|Dr. Anat Cohen-Dayag Ph.D.||Chief Exec. Officer, Pres and Director||575.36k||N/A||50|
|Mr. Ari Krashin||Chief Financial and Operating Officer||353.38k||N/A||44|
|Dr. Zurit Levine Ph.D.||VP of Research & Discovery||259.85k||N/A||49|
|Dr. John J. Hunter Ph.D.||VP of Antibody R&D||338.53k||N/A||54|
|Susanna Chau||Director of Investor Relations and Corp. Communications||N/A||N/A||N/A|
Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The companys pipeline primarily includes early and preclinical stage immuno-oncology programs based on novel drug targets, such as immune checkpoint and myeloid protein target candidates to harness the immune system to provide treatment solutions in the areas of unmet medical needs in various cancer types and patient populations. Its antibody drug conjugate target candidates comprise CGEN-15001T, CGEN-15022, CGEN-15029, and CGEN-15137 for oncology; and therapeutic proteins include CGEN-15001, a fusion protein for autoimmune diseases, as well as CGEN myeloid target. The company was incorporated in 1993 and is headquartered in Holon, Israel.
Compugen Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.